

Special Issue

Nanotechnology and Cell Therapies for Ocular Diseases

Message from the Guest Editors

We are pleased to announce a new Special Issue of *Pharmaceutics*, entitled “Nanotechnology and Cell Therapies for Ocular Diseases”, which is dedicated to showcasing recent advancements, innovative research, and emerging directions in this rapidly evolving field. Recent research has increasingly focused on nanotechnology and cell-based therapies for a wide spectrum of ocular diseases. From corneal to retinal reconstruction, nanostructured matrices and nanomedicine-based drug delivery systems hold great promise in addressing some of the most prevalent vision-threatening conditions worldwide, including cataracts, age-related macular degeneration, diabetic retinopathy, and glaucoma.

Stem cell therapy is another area of intense investigation that encompasses a range of transplantation methods and cultivation techniques. While clinical success has already been achieved with stem cell-based treatments for corneal ulcers caused by limbal stem cell deficiency, applications for retinal repair remain under active study.

This Special Issue warmly welcomes contributions from across multiple disciplines—including pharmacology, ophthalmology, bioengineering, and related fields.

Guest Editors

Prof. Dr. Raid Alany

1. Faculty of Science, Engineering and Computing, Kingston University London, Penrhyn Road, Kingston upon Thames, London KT1 2EE, UK
2. Faculty of Medical and Health Sciences, The University of Auckland, Auckland CBD, Auckland 1010, New Zealand

Dr. Ovidiu Samoilă

Department of Ophthalmology, Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania

Deadline for manuscript submissions

31 December 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/255101

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).